pCDCAR1 MART-1(DMF5) h(28), T(CAR-T-1-M310-2)
The vector of anti-MART-1(DMF5) chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human MART-1(DMF5). The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-MART-1(DMF5) antibody linked to CD28 signaling domains. And the vector product was designed for the treatment of metastatic melanoma.
Details
Targeting Cell Type
T cell
Targeting Diseases
Metastatic melanoma
Receptor Construction
scFv-CD28
Discription of Signaling Cassetes
CD28
CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide co-stimulatorysignals required for T cell activation and survival. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells(APC). CD28 modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. CD28 enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And CD28 results in a brightly expressed, stable receptor as the transmembrane domain. Including CD28 costimulatory domains in CARs led to enhanced anti-malignancy efficacy.
Antibody Host
Mouse and Human
Target
Synonyms
Melan-A; Antigen LB39-AA; Antigen SK29-AA; Protein Melan-A; MART-1; MART1; Melanoma Antigen Recognized By T-Cells 1
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Related Products
Carcinoma
Kits for CARs/TCRs Development